Perrigo (PRGO)

• Market cap: $2.91B
• 1 day: -0.05%
• 5 days: -5.76%
• 1 month: -8.29%
• 3 months: -19.76%
• 6 months: -24.22%
• Year to date: -18.77%
• 1 year: -25%
• 5 years: -55.13%
• 10 years: -88.17%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.

Employees: 8,379

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

374% more call options, than puts

Call options by funds: $31M | Put options by funds: $6.54M

36% more repeat investments, than reductions

Existing positions increased: 143 | Existing positions reduced: 105

3.25% more ownership

Funds ownership: 98.17% [Q1] → 101.43% (+3.25%) [Q2]

0% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 44

1% less capital invested

Capital invested by funds: $3.76B [Q1] → $3.73B (-$29M) [Q2]

1% less funds holding

Funds holding: 344 [Q1] → 339 (-5) [Q2]

17% less funds holding in top 10

Funds holding in top 10: 12 [Q1] → 10 (-2) [Q2]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $35
• Avg. target: $38
• High target: $40

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Canaccord Genuity Susan Anderson	$40	Buy Maintained	7 Aug 2025
JP Morgan Chris Schott	$35	Overweight Maintained	7 Aug 2025